Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Healthcare | Drug Manufacturers - Other | USA
statements
Index- P/E- EPS (ttm)-2.20 Insider Own0.10% Shs Outstand43.44M Perf Week-1.29%
Market Cap3.93B Forward P/E9.94 EPS next Y9.10 Insider Trans-16.78% Shs Float43.11M Perf Month10.73%
Income-93.60M PEG- EPS next Q2.56 Inst Own96.60% Short Float5.28% Perf Quarter10.52%
Sales1.52B P/S2.59 EPS this Y22.60% Inst Trans-2.14% Short Ratio5.07 Perf Half Y2.88%
Book/sh61.86 P/B1.46 EPS next Y912.50% ROA-2.40% Target Price128.00 Perf Year-18.51%
Cash/sh36.14 P/C2.50 EPS next 5Y- ROE-3.50% 52W Range74.31 - 128.94 Perf YTD-16.96%
Dividend- P/FCF- EPS past 5Y32.40% ROI19.00% 52W High-29.87% Beta0.96
Dividend %- Quick Ratio3.90 Sales past 5Y7.80% Gross Margin92.10% 52W Low21.69% ATR2.24
Employees860 Current Ratio4.10 Sales Q/Q-2.70% Oper. Margin-10.70% RSI (14)59.45 Volatility1.88% 2.60%
OptionableYes Debt/Eq0.37 EPS Q/Q24.30% Profit Margin-6.00% Rel Volume0.78 Prev Close89.53
ShortableYes LT Debt/Eq0.28 EarningsOct 30 BMO Payout- Avg Volume449.35K Price90.43
Recom2.40 SMA202.82% SMA507.36% SMA200-2.57% Volume351,742 Change1.01%
Aug-01-19Upgrade Ladenburg Thalmann Neutral → Buy $103 → $106
Aug-01-19Upgrade Jefferies Underperform → Hold $90
Jul-01-19Upgrade Credit Suisse Neutral → Outperform $98 → $101
May-17-19Upgrade UBS Sell → Neutral $115 → $94
May-09-19Upgrade Credit Suisse Underperform → Neutral $98
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
Dec-27-17Reiterated Wedbush Outperform $213 → $232
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Nov-14-19 07:00AM  Correvio Reports Third Quarter 2019 Financial Results CNW Group
Nov-08-19 08:56AM  Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks
Nov-04-19 11:38AM  Edited Transcript of UTHR earnings conference call or presentation 30-Oct-19 1:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 11:45AM  United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up Zacks
06:50AM  Will United Therapeutics Continue to Surge Higher? Zacks
Oct-30-19 10:54AM  Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial Zacks
07:30AM  United Therapeutics (UTHR) Tops Q3 Earnings and Revenue Estimates Zacks
06:00AM  United Therapeutics Corporation Reports Third Quarter 2019 Financial Results PR Newswire
Oct-29-19 10:40AM  Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards? Zacks
10:10AM  Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? Zacks
08:44AM  5 Solid Relative Price Strength Stocks to Make You Rich Zacks
Oct-25-19 11:28AM  United Therapeutics Corporation (UTHR): Hedge Funds Had A Change of Heart Insider Monkey
Oct-23-19 10:33AM  Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks
06:00AM  United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019 PR Newswire
Oct-21-19 06:00AM  United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study PR Newswire
Oct-18-19 11:12AM  Does United Therapeutics Corporation (NASDAQ:UTHR) Have A Volatile Share Price? Simply Wall St.
Oct-14-19 09:15AM  Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out? Zacks
Oct-02-19 05:00AM  Some local CEOs are paid much more than their employees here's how much American City Business Journals
Sep-18-19 05:58AM  Investors Who Bought United Therapeutics (NASDAQ:UTHR) Shares Five Years Ago Are Now Down 38% Simply Wall St.
Sep-12-19 11:25AM  United Therapeutics' Trevyent NDA for PAH Accepted by FDA Zacks
07:00AM  Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application CNW Group
Sep-11-19 06:00AM  United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review PR Newswire
Aug-23-19 12:00PM  MNKD: Q2 2019: Record Revenue, Margins as Rx Continue to Ramp. Clinical Evidence Driving Adoption Zacks Small Cap Research
Aug-19-19 04:35PM  iBio Inks 3D Bioprinting Agreement GlobeNewswire
Aug-16-19 09:24AM  Is United Therapeutics Corporation's (NASDAQ:UTHR) CEO Paid Enough Relative To Peers? Simply Wall St.
Aug-14-19 07:00AM  Correvio Reports Second Quarter 2019 Financial Results CNW Group
Aug-10-19 08:32AM  Edited Transcript of UTHR earnings conference call or presentation 31-Jul-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-09-19 09:25AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
Aug-08-19 11:23AM  MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript Motley Fool
10:34AM  Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet Zacks
Aug-06-19 06:00AM  United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-01-19 09:49AM  United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y Zacks
Jul-31-19 11:01PM  United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript Motley Fool
02:44PM  United Therapeutics is executing its growth plan. Why isnt its stock price higher? American City Business Journals
07:30AM  United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates Zacks
06:00AM  United Therapeutics Corporation Reports Second Quarter 2019 Financial Results PR Newswire
Jul-24-19 06:00AM  United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019 PR Newswire
Jul-17-19 01:00PM  What You Should Know About United Therapeutics Corporation's (NASDAQ:UTHR) Financial Strength Simply Wall St.
Jul-11-19 12:25AM  Sexual harassment lawsuit against Md. biotech to advance with plaintiff's identity revealed American City Business Journals
Jul-03-19 09:15AM  S&P Makes It Two Record Closes in a Row Zacks
Jul-01-19 02:37PM  Credit Suisse: United Therapeutics Becoming More Fundamentally Driven Benzinga +5.11%
09:28AM  United Therapeutics Stock Jumps After Analyst Says Its Slide Was Overdone Barrons.com
Jun-26-19 09:15AM  Stocks Slide as Fed Dampens Rate Cut Expectations Zacks
Jun-18-19 10:38AM  Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod Zacks
Jun-17-19 02:59PM  Have Insiders Been Selling United Therapeutics Corporation (NASDAQ:UTHR) Shares? Simply Wall St.
Jun-13-19 11:19AM  Heres What Hedge Funds Think About United Therapeutics Corporation (UTHR) Insider Monkey
Jun-10-19 01:01PM  Impact on Jacksonville of mega-merger of United Technologies and Raytheon is uncertain American City Business Journals
Jun-05-19 06:00AM  United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
May-28-19 06:00AM  United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference PR Newswire
May-23-19 11:42AM  The Catalyst: Creating Innovation in Health Care - United Therapeutics' Martine Rothblatt at Healthy Returns CNBC Videos
May-09-19 09:03AM  Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up Zacks
May-08-19 03:50PM  Before You Buy United Therapeutics Corporation (NASDAQ:UTHR), Consider Its Volatility Simply Wall St.
09:24AM  MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 03:27PM  Edited Transcript of UTHR earnings conference call or presentation 1-May-19 1:00pm GMT Thomson Reuters StreetEvents
06:00AM  United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin® PR Newswire
May-02-19 05:25PM  United Therapeutics zeroes in on new business lines in wake of generic competition American City Business Journals
09:26AM  United Therapeutics (UTHR) Down Despite Q1 Earnings Beat Zacks
May-01-19 01:16PM  United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates Zacks
12:45PM  United Therapeutics Corporation (UTHR) Q1 2019 Earnings Call Transcript Motley Fool
06:16AM  United Therapeutics: 1Q Earnings Snapshot Associated Press
06:00AM  United Therapeutics Corporation Reports First Quarter 2019 Financial Results PR Newswire
Apr-29-19 06:00AM  United Therapeutics Announces FDA Approval Of XPS And Steen Solution Used To Perform Centralized Ex-Vivo Lung Perfusion Services PR Newswire
Apr-24-19 10:33AM  United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
06:00AM  United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019 PR Newswire
Apr-23-19 09:09PM  Is United Therapeutics Corporation (UTHR) A Good Stock To Buy? Insider Monkey +5.53%
Apr-17-19 10:52PM  United Therapeutics Issues Statement In Response To Meritless Lawsuit PR Newswire -5.93%
Apr-12-19 01:16PM  Is United Therapeutics Corporation's (NASDAQ:UTHR) Liquidity Good Enough? Simply Wall St.
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 10:06AM  United Therapeutics Discontinues PAH Drug After Study Fails Zacks
09:30AM  Company News For Apr 9, 2019 Zacks
Apr-08-19 02:52PM  United Therapeutics drops drug prospect after failed trial American City Business Journals -5.70%
12:48PM  Stocks making the biggest moves midday: Snap, GE, Boeing, AMC & more CNBC
06:00AM  United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint PR Newswire
Apr-01-19 08:00AM  Report: Exploring Fundamental Drivers Behind Coeur Mining, Owens & Minor, Telenav, Cedar Realty Trust, j2 Global, and United Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-29-19 09:30AM  United Therapeutics (UTHR) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-28-19 03:10PM  Supernus reports mixed ADHD drug trial results. So why isn't it worried? American City Business Journals
Mar-12-19 06:00AM  United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference PR Newswire
Mar-11-19 12:48PM  Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years Simply Wall St.
Mar-05-19 10:55AM  MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results Zacks Small Cap Research
Mar-04-19 06:00AM  United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference PR Newswire -5.30%
Mar-01-19 10:19PM  Edited Transcript of UTHR earnings conference call or presentation 27-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 10:16AM  United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates Zacks
Feb-27-19 03:31PM  United Therapeutics Corp (UTHR) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:25AM  Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues Zacks
06:00AM  United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results PR Newswire
Feb-26-19 05:55PM  MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:43PM  Here's Why MannKind Rocketed Higher Today Motley Fool
Feb-20-19 06:00AM  United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019 PR Newswire
Feb-13-19 10:31AM  Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks
10:00AM  Does United Therapeutics Corporations (NASDAQ:UTHR) CEO Salary Reflect Performance? Simply Wall St.
Jan-31-19 08:00PM  Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress PR Newswire
Jan-28-19 07:45AM  Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-25-19 07:38AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug Benzinga
Jan-24-19 08:00PM  United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag PR Newswire
08:00PM  Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag PR Newswire
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
Jan-08-19 09:54AM  Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares? Simply Wall St.
Dec-31-18 06:00AM  United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-17-18 10:11PM  United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock? Insider Monkey
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DWEK RAYMONDDirectorJun 27Sale76.113,750285,4130Jun 28 04:25 PM
DWEK RAYMONDDirectorJun 26Option Exercise0.003,75003,750Jun 28 04:25 PM
Thompson Tommy GDirectorJun 26Option Exercise0.001,870021,940Jun 28 04:24 PM
KURZWEIL RAYDirectorJun 26Option Exercise0.001,87005,240Jun 28 04:18 PM
Olian Judy D.DirectorJun 26Option Exercise0.001,87008,000Jun 28 04:20 PM
Giltner RichardDirectorJun 26Option Exercise0.003,75003,750Jun 28 04:15 PM
SULLIVAN LOUIS WDirectorJun 26Option Exercise0.003,75005,120Jun 28 04:13 PM
Giltner RichardDirectorJun 20Option Exercise41.145,000205,7005,000Jun 21 09:03 AM
Giltner RichardDirectorJun 20Sale79.055,000395,2500Jun 21 09:03 AM
Giltner RichardDirectorJun 13Option Exercise41.145,000205,7005,000Jun 13 04:04 PM
Giltner RichardDirectorJun 06Option Exercise41.145,000205,7005,000Jun 06 04:01 PM
Giltner RichardDirectorMay 30Option Exercise41.145,000205,7005,000May 31 04:07 PM
Giltner RichardDirectorApr 05Option Exercise41.145,000205,7005,000Apr 05 04:10 PM
CAUSEY CHRISTOPHERDirectorApr 04Option Exercise63.9075047,9251,725Apr 05 04:11 PM
MAHON PAUL AEVP & General CounselMar 21Option Exercise92.536,000555,18041,323Mar 22 04:11 PM
PATUSKY CHRISTOPHERDirectorMar 20Option Exercise54.775,000273,8505,000Mar 22 04:16 PM
ROTHBLATT MARTINE AChairman & CEOMar 19Option Exercise52.657,055371,4467,195Mar 20 04:03 PM
ROTHBLATT MARTINE AChairman & CEOMar 18Option Exercise52.657,055371,4467,195Mar 20 04:03 PM
Thompson Tommy GDirectorMar 18Option Exercise52.6517,100900,31520,070Mar 19 05:35 PM
CAUSEY CHRISTOPHERDirectorMar 14Option Exercise63.9075047,9251,725Mar 18 08:03 AM
MAHON PAUL AEVP & General CounselMar 07Option Exercise65.806,000394,80041,823Mar 08 04:01 PM
PATUSKY CHRISTOPHERDirectorMar 07Sale110.753,370373,2280Mar 08 04:02 PM
SULLIVAN LOUIS WDirectorMar 01Option Exercise54.771,00054,7702,370Mar 04 05:25 PM
MAHON PAUL AEVP & General CounselFeb 21Option Exercise65.806,000394,80041,613Feb 22 05:49 PM
CAUSEY CHRISTOPHERDirectorFeb 07Option Exercise63.9075047,9251,725Feb 08 04:03 PM
MAHON PAUL AEVP & General CounselFeb 07Option Exercise65.806,000394,80041,613Feb 08 04:02 PM
Thompson Tommy GDirectorFeb 05Sale117.0040046,8002,970Feb 05 04:28 PM
ROTHBLATT MARTINE AChairman & CEOJan 31Option Exercise52.657,054371,3937,194Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 31Sale115.307,054813,349140Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Sale115.847,054817,160140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Sale115.707,054816,176140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Sale115.577,054815,238140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Sale115.167,054812,359140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Sale113.957,054803,780140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Sale112.947,054796,709140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Sale113.357,054799,591140Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 18Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
CAUSEY CHRISTOPHERDirectorJan 18Option Exercise63.9075047,9251,725Jan 22 05:01 PM
ROTHBLATT MARTINE AChairman & CEOJan 18Sale115.157,054812,285140Jan 23 08:28 AM
MAHON PAUL AEVP & General CounselJan 17Option Exercise65.806,000394,80041,613Jan 18 04:07 PM
ROTHBLATT MARTINE AChairman & CEOJan 17Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 17Sale113.797,054802,679140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Sale113.617,054801,423140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Sale114.867,054810,200140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Sale114.847,054810,056140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 11Option Exercise52.657,054371,3937,194Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 11Sale113.597,054801,235140Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 10Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 10Sale113.597,054801,235140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Sale113.437,054800,121140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 08Option Exercise52.657,054371,3937,194Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 08Sale113.167,054798,220140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Option Exercise52.657,055371,4467,195Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Sale113.407,055800,056140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 04Option Exercise52.657,055371,4467,195Jan 07 06:38 PM
ROTHBLATT MARTINE AChairman & CEOJan 04Sale111.517,055786,719140Jan 07 06:38 PM
MAHON PAUL AEVP & General CounselJan 03Option Exercise65.806,000394,80041,613Jan 04 04:01 PM
SULLIVAN LOUIS WDirectorJan 02Option Exercise54.771,00054,7702,370Jan 03 04:02 PM
MAHON PAUL AEVP & General CounselDec 20Option Exercise65.806,000394,80041,613Dec 21 04:06 PM
Thompson Tommy GDirectorDec 11Option Exercise52.6590047,3854,270Dec 11 04:04 PM
MAHON PAUL AEVP & General CounselDec 06Option Exercise62.4810,000624,82042,613Dec 07 04:02 PM
SULLIVAN LOUIS WDirectorDec 03Option Exercise54.771,00054,7702,370Dec 04 04:04 PM
open in yahoo | open in reuters | open in google